Wiley Blackwell

SHERPA: Unknown

People

  1. Bajorin
    Bajorin
  2. Bosl
    Bosl
  3. Motzer
    Motzer
  4. Al-Ahmadie
    Al-Ahmadie
  5. Herr
    Herr
  6. Iyer
    Iyer
  7. Rosenberg
    Rosenberg
  8. Bochner
    Bochner
  9. Ostrovnaya
    Ostrovnaya
  10. Scher
    Scher

Groups

  1. Department of Medicine (40)
  2. Genitourinary Oncology Service (40)
  3. Solid Tumor Oncology Division (40)
  4. Survivorship Research (16)
  5. Surgery (15)
  6. Urology (15)
  7. Department of Pathology and Laboratory Medicine (10)
  8. Biostatistics Service (9)
  9. Epidemiology and Biostatistics (9)
  10. Nursing (5)
Search Within
  1. "Dean Bajorin"
Formats
  1. Journal Article (36)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (40)
  2. Genitourinary Oncology Service (40)
  3. Solid Tumor Oncology Division (40)
  4. Survivorship Research (16)
  5. Surgery (15)
  6. Urology (15)

More Groups

People
  1. Dean Bajorin (40)
  2. George Bosl (12)
  3. Robert Motzer (9)
  4. Hikmat Al-Ahmadie (8)
  5. Matthew Milowsky (8)
  6. Gopakumar Iyer (7)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (2)
  5. 2019 (2)
  6. 2017 (2)

More Years

Publications
  1. Cancer (26)
  2. BJU International (6)
  3. Asia-Pacific Journal of Clinical Oncology (4)
  4. Journal of Pathology (2)
  5. Cancer Medicine (1)
  6. International Journal of Andrology (1)

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors
    Journal Article

    Funt, S. A.; Knezevic, A.; Wilson, K.; Bromberg, M.; Budnick, A.; O’Connor, K. L.; McHugh, D. J.; Larsen, E.; Bajorin, D. F.; Motzer, R. J.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma
    Journal Article

    Vanguri, R. S.; Smithy, J. W.; Li, Y.; Zhuang, M.; Maher, C. A.; Aleynick, N.; Peng, X.; Al-Ahmadie, H.; Funt, S. A.; Rosenberg, J. E.; more...
    Journal of Pathology (2023)

    Fulltext@MSK | Save
  • Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy
    Journal Article

    Almassi, N.; Vertosick, E. A.; Sjoberg, D. D.; Wong, N. C.; Huang, C.; Pietzak, E. J.; Cha, E. K.; Donahue, T. F.; Dalbagni, G.; Bochner, B. H.; more...
    BJU International (2022)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
    Journal Article

    McPherson, V.; Reardon, B.; Bhayankara, A.; Scott, S. N.; Boyd, M. E.; Whiting, K.; Garcia-Grossman, I. R.; Regazzi, A. M.; McCoy, A. S.; Kim, P. H.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results
    Journal Article

    Pal, S. K.; Bajorin, D.; Dizman, N.; Hoffman-Censits, J.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U.; De Giorgi, U.; Gupta, S.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Updated interim analysis from Keynote-057: Pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)
    Meeting Abstract

    Krieger, L.; de Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J. L.; Roumiguie, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Impact of prognostic factors and risk groups on overall survival in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer: Post HOC analysis of Keynote-045
    Meeting Abstract

    Gurney, H.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Keynote-045: Open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
    Meeting Abstract

    Quinn, D.; Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) of pembrolizumab vs chemotherapy for previously treated advanced urothelial cancer (UC) in KEYNOTE-045
    Meeting Abstract

    Quinn, D.; Vaughn, D. J.; Bellmunt, J.; de Wit, R.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save